Edgeworth Client Receives Settlement in Patent Dispute

Edgeworth Partner Dr. Jesse David, head of Edgeworth’s Los Angeles office, provided expert economic analysis on behalf of Santarus Inc., the exclusive licensee of two patents covering the heartburn medication Zegerid®, in Santarus’s suit against Par Pharmaceutical Cos. 

Dr.  David developed analyses of lost profits and reasonable royalties related to Par’s at-risk launch of a generic version of Zegerid®. He prepared an expert report on his findings and testified in deposition.

Santarus and Par reached a settlement two months prior to trial, with Par paying Santarus $100 million.


Jump to Page

This website uses cookies to improve functionality and performance. By continuing to use this website, you agree to the use of cookies in accordance with our Privacy Policy.  If you are a California resident, read our California Information Practices.